Peripheral Arterial DiseaseAxys ACHIEVENCT04282161
Pivotal Study of the Medtronic Axys EX Rotational Atherectomy System
A study testing Axys EX device in people with Peripheral Arterial Disease, run by Medtronic Endovascular.
Trial summary
The primary objective is to demonstrate the safety and effectiveness of the Axys EX rotational atherectomy system in subjects with peripheral arterial disease who have de novo or non-stented restenotic obstructive lesions in the peripheral vasculature of the lower limbs. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Peripheral Arterial Disease
- What is being tested?
- Axys EX device
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- Dec 2021to Feb 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
General Inclusion Criteria:
- Rutherford Clinical Category (RCC) Score of 2 - 5
- Willing and capable of complying with all follow-up evaluations at the specified times
- Age ≥ 18 years old
- Provides written informed consent prior to study specific procedures
- Completed Ankle/Brachial Index (ABI) (or Toe/Brachial Index [TBI]) prior to index procedure (up to 60 days prior) Angiographic Inclusion Criteria:
- Evidence of ≥ 70% stenosis or occlusion in the peripheral vasculature of the target vessel, confirmed by angiography
- Target lesion present in a single limb that consists of a single de novo or non-stented restenotic lesion, or qualifies as a tandem or combination lesion per the definitions below:
- Tandem (adjacent) Lesion: Lesions present in the same target vessel that can be treated as one single lesion and is separated by an angiographic normal vessel ≤3 cm at any point. Multiple points of separation can be present in single lesion treatment if no single point of separation is > 3 cm
- Combination Lesion: A single lesion that is not completely occluded but includes a segment of complete occlusion anywhere along the length
- Exchangeable guidewire must cross target lesion within the lumen
- Total target lesion length is ≥ 20 mm and ≤ 200mm
- Reference vessel diameter (RVD) is ≥ 2.0 mm and ≤ 5.0 mm
- Identifiable distal target vessel which upon completion of the intervention is anticipated to provide reconstitution of blood flow to the foot. Angiographic evidence of adequate distal runoff through the foot (at least one native calf vessel [posterior tibial, anterior tibial, or peroneal artery] is patent, defined as < 50% stenosed)
- Multiple lesions in the target limb (including the target lesion and non-target lesions) may be treated if all of the following applies:
- Non-target lesion(s) must be located proximal to the target lesion
- Non-target lesion(s) must be successfully treated (defined as optimally treated [e.g. no untreated arterial dissections or perforation present]) by standard endovascular procedures prior to initiation of treatment of the target lesion
- Non-target lesions treated prior to target lesion cannot be treated with rotational, orbital or laser atherectomy
- Non-target lesion(s) may be located in separate vascular beds (i.e., iliac,femoropopliteal, tibial) or multiple tibial vascular beds (i.e., anterior tibial, posterior tibial, tibioperoneal trunk/peroneal). (Note: Only one tibial vessel may be identified as the target vessel with the target lesion.)
- Only one lesion per the above definitions may be treated as the target lesion with the Axys EX device General Exclusion Criteria:
- Has one or more of the contraindications listed in the Axys EX Rotational Atherectomy System's IFU
- Contraindication or known untreated allergy to antiplatelet therapy, anticoagulants, thrombolytic drugs, or any other drug anticipated to be used
- Hypersensitivity to contrast material that cannot be adequately pretreated
- Known uncontrollable hypercoagulable condition or refuses blood transfusion
- Life expectancy of less than 12 months
- Surgical (requiring hospitalization) or endovascular intervention of the target limb within 30 days prior to the index procedure
- Planned surgical intervention or endovascular procedure within 30 days after the index procedure
- Currently participating in an investigational drug or another device study that may clinically interfere with the study endpoints
- Other co-morbid condition(s) that in the judgment of the physician precludes safe percutaneous intervention
- If a previous peripheral bypass affecting the target limb is present, the bypass must be patent and the target lesion cannot be present in the peripheral bypass artery
- Impaired renal function (defined as GFR < 30 mL/min) or on dialysis
- Recent myocardial infarction or stroke ≤ 30 days prior to the index procedure
- Previous or planned amputation above the metatarsal line on the target limb
- Patient belongs to a vulnerable population per investigator's judgment or patient has any kind of disorder that compromises his/her ability to give written informed consent and/or to comply with study procedures. Patient must be able to consent for themselves
- Patient is pregnant (female patients of child-bearing potential must have a pregnancy test done within 7 days prior to the index procedure) Angiographic Exclusion Criteria:
- Noted thrombus at the point of the intended target lesion
- In-stent restenosis of the target lesion
- Aneurysmal target vessel
- Hemodynamic significant stenosis or occlusion of inflow tract that has not been revascularized prior to treatment of the target vessel
- Perforation, flow limiting dissection or other injury of the target vessel requiring surgical intervention prior to enrollment
- Disease that precludes safe advancement of the Axys EX device to the target lesion
- Need to treat a lesion distal to the target index lesion
About this study
Official title: Pivotal Study of the Medtronic Axys EX Rotational Atherectomy System for the Treatment of Peripheral Arterial Disease in the Vasculature of the Lower Limbs
The primary objective is to demonstrate the safety and effectiveness of the Axys EX rotational atherectomy system in subjects with peripheral arterial disease who have de novo or non-stented restenotic obstructive lesions in the peripheral vasculature of the lower limbs.
- Conditions
- Peripheral Arterial Disease
- Being tested
- Axys EX device
- Keywords
- Peripheral Vascular Disease, Critical Limb Ischemia, Superficial Femoral Artery Stenosis, Atherosclerosis, Arteriosclerosis, Vascular Diseases, Arterial Disease Occlusive, lower extremity arterial disease
- Medical subject headings
- Peripheral Arterial Disease, Peripheral Vascular Diseases, Chronic Limb-Threatening Ischemia, Atherosclerosis, Arteriosclerosis, Vascular Diseases, Arterial Occlusive Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Axys EX deviceDevice
Also called Axys EX
Rotational atherectomy system for endovascular treatment of peripheral arterial disease prior to adjunctive therapy, if needed
| Study group | Role | What they receive |
|---|---|---|
| Axys EX device | Experimental | Not described Receives: Device: Axys EX device |
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary Effectiveness
Change in percent stenosis in the treatment vessel. Percent stenosis is defined as native vessel diameter as measured at the narrowest point of the lesion divided by the estimated native vessel diameter at that location.
Measured: During procedure
Primary Safety
Major Adverse Events (MAEs) at 30 Days post-procedure defined as freedom from clinically-driven target lesion revascularization (CD-TLR), major unplanned amputation of the treated limb, or all-cause mortality.
Measured: 30-Days
Secondary outcomes (16)
Technical Success
Defined as the ability of the Axys EX device to successfully traverse/cross the entire intended length of the target lesion
Measured: During Procedure
Procedural Success
Defined as ≤ 30% residual stenosis following use of the Axys EX device and adjunctive therapy as measured by angiography and determined by the angiographic core laboratory
Measured: During Procedure
Amputation-Free Survival
Defined as freedom from a major, unplanned amputation of the target limb through the 12 month visit
Measured: 12-Months
Major Adverse Events (MAEs)
Defined as freedom from clinically-driven target vessel revascularization (CD-TVR), major unplanned amputation of the treated limb, thrombosis at the target lesion site, or all-cause mortality
Measured: 12-Months
Rate of Target Lesion Revascularization (TLR)
Any re-intervention at the target lesion
Measured: 6 and 12-Months
Rate of Target Vessel Revascularization (TVR)
Any re-intervention within the target vessel
Measured: 6 and 12-Months
Provisional Stent Rate
Measured: During Procedure
Flow Limiting Dissection
Target lesion flow limiting dissection (D or greater) rate after adjunctive therapy
Measured: During Procedure
Primary Patency as determined by Duplex Ultrasound (DUS)
- For subjects with a target lesion in the femoropopliteal region (above the knee [ATK]) through the level of popliteal segment P3 (below the knee popliteal artery from the center of the knee joint space to the origin of anterior tibial artery), primary patency is defined as freedom from core laboratory-assessed restenosis (DUS PSVR ≤2.4) and CD-TLR (adjudicated by a Clinical Events Committee)
- For subjects with a target lesion below the level of popliteal segment P3 (below the knee [BTK]), primary patency is defined as freedom from core laboratory-assessed absence of target lesion occlusion (no flow) as assessed by DUS and CD-TLR (adjudicated by a Clinical Events Committee)
Measured: 6 and 12-Months
Quality of Life Assessment
EQ-5D questionnaire
Measured: 30-Days, 6 and 12-Months
Walking Distance
6-Minute Walking Test
Measured: 30-Days, 6 and 12-Months
Walking Capacity
Walking Impairment Questionnaire (WIQ)
Measured: 30-Days, 6 and 12-Months
Ankle/brachial index (ABI) or toe/brachial index (TBI)
Measured: 30-Days, 6 and 12-Months
Rutherford clinical category (RCC)
Measured: 30-Days, 6 and 12-Months
Distal Embolization in Target Limb
Clinically significant distal embolization in target limb within 30 days defined as distal embolization requiring treatment by mechanical or pharmacologic means (other than a vasodilator) (adjudicated by a Clinical Events Committee)
Measured: 30-Days
Major Vessel Perforation
requiring surgical or endovascular repair within 30 days (adjudicated by a Clinical Events Committee) 6.
Measured: 30-Days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Feb 2020
- Study startDec 2021 (estimated)
- Primary completionAug 2023 (estimated)
- Study completionFeb 2024 (estimated)
Why it stopped: Business Decision
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Peripheral Arterial DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Medtronic Endovascular
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Ravish Sachar, MD FACC, Principal investigator, North Carolina Heart and VascularBrian DeRubertis, MD FACS, Principal investigator, University of California, Los Angeles
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04282161
- Sponsor's protocol ID
- MDT17045
- Acronym
- Axys ACHIEVE
- Status last verified
- Mar 2021
- First submitted
- 18 Feb 2020
- Last updated
- 5 Apr 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Apr 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pivotal Study of the Medtronic Axys EX Rotational Atherectomy System for the Treatment of Peripheral Arterial Disease in the Vasculature of the Lower Limbs
- ClinicalTrials.gov ID
- NCT04282161
- Acronym / sponsor ID
- Axys ACHIEVE / MDT17045
- Conditions
- Peripheral Arterial Disease
- Keywords
- Peripheral Vascular Disease, Critical Limb Ischemia, Superficial Femoral Artery Stenosis, Atherosclerosis, Arteriosclerosis, Vascular Diseases, Arterial Disease Occlusive, lower extremity arterial disease
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: Business Decision
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Medtronic EndovascularIndustry (pharma, biotech, devices)
- Study start
- Dec 2021 (estimated)
- Primary completion
- Aug 2023 (estimated)
- Study completion
- Feb 2024 (estimated)
- First posted
- 24 Feb 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective is to demonstrate the safety and effectiveness of the Axys EX rotational atherectomy system in subjects with peripheral arterial disease who have de novo or non-stented restenotic obstructive lesions in the peripheral vasculature of the lower limbs.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Axys EX device | Experimental | Device: Axys EX device |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Axys EX deviceAlso: Axys EXRotational atherectomy system for endovascular treatment of peripheral arterial disease prior to adjunctive therapy, if needed | Device | Axys EX device |
Primary outcome
Primary Effectiveness
Time frame: During procedure
Change in percent stenosis in the treatment vessel. Percent stenosis is defined as native vessel diameter as measured at the narrowest point of the lesion divided by the estimated native vessel diameter at that location.
Primary Safety
Time frame: 30-Days
Major Adverse Events (MAEs) at 30 Days post-procedure defined as freedom from clinically-driven target lesion revascularization (CD-TLR), major unplanned amputation of the treated limb, or all-cause mortality.
16 secondary outcomes
Technical Success
Time frame: During Procedure
Procedural Success
Time frame: During Procedure
Amputation-Free Survival
Time frame: 12-Months
Major Adverse Events (MAEs)
Time frame: 12-Months
Rate of Target Lesion Revascularization (TLR)
Time frame: 6 and 12-Months
Rate of Target Vessel Revascularization (TVR)
Time frame: 6 and 12-Months
Provisional Stent Rate
Time frame: During Procedure
Flow Limiting Dissection
Time frame: During Procedure
Primary Patency as determined by Duplex Ultrasound (DUS)
Time frame: 6 and 12-Months
Quality of Life Assessment
Time frame: 30-Days, 6 and 12-Months
Walking Distance
Time frame: 30-Days, 6 and 12-Months
Walking Capacity
Time frame: 30-Days, 6 and 12-Months
Ankle/brachial index (ABI) or toe/brachial index (TBI)
Time frame: 30-Days, 6 and 12-Months
Rutherford clinical category (RCC)
Time frame: 30-Days, 6 and 12-Months
Distal Embolization in Target Limb
Time frame: 30-Days
Major Vessel Perforation
Time frame: 30-Days
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Apr 2021.
- Individual participant dataSharing planned: No
Related trials for Peripheral Arterial Disease
Active, not recruiting
SUCCESS (SelUtion, Safety, effiCaCy, hEalth economicS and promS) PTA Study
Peripheral Artery Disease
RecruitingPhase 3
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
Peripheral Artery Disease (PAD)
Recruiting
The THOR IDE Study
Peripheral Artery Disease, Peripheral Artery Stenosis
Not yet recruiting
Daily Stretching to Improve Walking in Older Patients With Peripheral Artery Disease: The STRETCH PAD Study
Peripheral Artery Disease (PAD), Intermittent Claudication
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ravish Sachar, MD FACC principal investigator
North Carolina Heart and Vascular
Brian DeRubertis, MD FACS principal investigator
University of California, Los Angeles
Questions about this trial
What is this clinical trial studying?
A study testing Axys EX device in people with Peripheral Arterial Disease, run by Medtronic Endovascular.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 5 Apr 2021. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Primary Effectiveness (time frame: During procedure). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Apr 2021.